Living Cell Technologies - Latest News [Page 1]

Withdrawal of NTCELL pre-clinical study

Thursday, 20 February 2014, 4:00 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that it is withdrawing the publication of the pre-clinical study of the effects of NTCELL in a rat model of Parkinson’s disease. The data will also be withdrawn from all regulatory documentation. More >>

NTCELL clinical trial: Recruitment of further patients

Monday, 25 November 2013, 1:35 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that the independent data safety monitoring board (DSMB) has reviewed the safety data from the initial patient in the Phase I/IIa clinical trial of NTCELL and advised that implants for the additional ... More >>

Living Cell Technologies a finalist

Thursday, 28 March 2013, 12:05 pm | Living Cell Technologies

Living Cell Technologies a finalist in 2013 New Zealand Hi-Tech Awards Auckland, 28 March 2013 – Living Cell Technologies was last night announced as a finalist in the 2013 New Zealand Hi-Tech Awards. The company is a finalist in the Cisco Hi-Tech ... More >>

Living Cell Technologies Awarded NZBIO Company of the Year

Wednesday, 20 March 2013, 11:09 am | Living Cell Technologies

Living Cell Technologies Limited Company Announcement Living Cell Technologies Awarded NZBIO Company of the Year More >>

LCT appoints Chief Science and Medical Officer

Monday, 10 December 2012, 11:46 am | Living Cell Technologies

10 December, 2012 Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the appointment of Dr Paul Tan to the position of Chief Science and Medical Officer (CSMO). More >>

LCT starts DIABECELL® Phase IIb trial

Thursday, 22 November 2012, 1:33 pm | Living Cell Technologies

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a Phase IIb trial of DIABECELL®. More >>

Strong interim result in Phase I/IIa DIABECELL® trial

Thursday, 22 November 2012, 1:21 pm | Living Cell Technologies

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the results of an interim analysis of its Argentinian Phase I/IIa clinical trial for DIABECELL®, a breakthrough treatment ... More >>

LCT CEO Dr Andrea Grant appointed Managing Director

Friday, 16 November 2012, 12:43 pm | Living Cell Technologies

16 November 2012: Sydney, Australia and Auckland, New Zealand – Roy Austin, chairman of Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), is pleased to announce the appointment of Dr Andrea Grant to the board as Managing Director. Dr Grant joined ... More >>

Ethical approval for LCT’s NTCELL® Phase I trial

Friday, 16 November 2012, 12:02 pm | Living Cell Technologies

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase ... More >>

Otsuka commits $A25 million to JV with LCT

Wednesday, 19 October 2011, 2:29 pm | Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has agreed to establish a 50/50 joint venture company DIATRANZ OTSUKA LIMITED with Otsuka Pharmaceutical Factory, Inc. (“Otsuka”) to accelerate the commercialisation of LCT’s DIABECELL®, ... More >>

Cost of treating Type 1 diabetes could double to $340bn

Wednesday, 19 October 2011, 12:28 pm | Living Cell Technologies

The cost of treating Type 1 diabetes for Australia is a massive $170bn – and the bill could double. Diabetes is the world’s fastest growing chronic disease affecting 220 million people worldwide. In Australia, it is the sixth leading cause of death ... More >>

World Leading Treatment for Diabetes Gathers Pace

Monday, 22 August 2011, 1:40 pm | Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant to treat diabetes, has implanted the first two patients taking part in a Phase II DIABECELL® clinical trial in Buenos Aires, Argentina. More >>

LCT Enrols First Patients in DIABECELL® Argentina Trial

Monday, 27 June 2011, 1:42 pm | Living Cell Technologies

• Enrolment of first two patients signifies the commencement of the Phase II clinical trial, ahead of schedule • Pre-transplant patient monitoring initiated • First DIABECELL transplants at 5,000 IEQ/kg scheduled for August 2011 More >>

Living Cell Technologies Founder wins Prestigious Award

Thursday, 10 March 2011, 3:12 pm | Living Cell Technologies

10 March 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that Medical Director and ... More >>

LCT Receives Funds from Pharmaceutical Investor

Wednesday, 9 March 2011, 1:00 pm | Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, confirmed today the receipt of A$1.7 million from Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK) in ... More >>

LCT granted vital Australian patent

Thursday, 24 February 2011, 1:20 pm | Living Cell Technologies

Thursday 24th February, 2011: Sydney, Australia, Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been ... More >>

Revolutionary treatment for Type 1 diabetes

Wednesday, 16 February 2011, 1:21 pm | Living Cell Technologies

Two international charitable foundations, New Zealand-based Cure Kids and U.S.-based Children with Diabetes Foundation, have each pledged to provide US$140,000 to fund the final two patients in a Phase II clinical trial in New Zealand that has the potential ... More >>

LCT reports sustained improvement from DIABECELL

Wednesday, 27 October 2010, 4:04 pm | Living Cell Technologies

27 October 2010: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of cell implants to treat diabetes, today reported continuing positive results from ... More >>

LCT receives approval to expand DIABECELL® Trial

Wednesday, 4 August 2010, 1:49 pm | Living Cell Technologies

4 August 2010: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant to treat diabetes, today reported that the Minister of Health has ... More >>

LCT reports consistent benefit from implants

Tuesday, 13 July 2010, 1:32 pm | Living Cell Technologies

13 July 2010: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of cell implants to treat diabetes, today reported further positive results from the ... More >>

  next>

 

InfoPages Links

 
 
 
 
 

LATEST HEADLINES

 
 
 
InfoPages
Search Scoop  
 
 
Powered by Vodafone
NZ independent news